Glucagon-like peptide 1 receptor agonists have been shown to reduce all-cause and cardiovascular mortality in patients with Type 2 diabetes mellitus (T2DM). The probable increase in heart rate hinders its early usage in acute myocardial infarction patients. In our study, we aimed to find out whether the use of liraglutide in patients with acute myocardial infarction as early as at the time of hospitalization would increase the heart rate.

中文翻译：

---

利拉鲁肽不会增加糖尿病患者急性心肌梗死期间的心率

胰高血糖素样肽 1 受体激动剂已被证明可以降低 2 型糖尿病 (T2DM) 患者的全因死亡率和心血管死亡率。心率可能增加阻碍了其在急性心肌梗死患者中的早期使用。在我们的研究中，我们的目的是查明急性心肌梗死患者在住院时使用利拉鲁肽是否会增加心率。